Adults treated with amlitelimab showed sustained improvement in their moderate to severe atopic dermatitis over the span of 28 weeks, Sanofi announced in a press release.
The study was designed with two parts, the first being a 24-week treatment period and the second being the current, ongoing 36-week maintenance period. These 28-week results, derived from the second part of the study, were presented in a late-breaker session at the American Academy of Dermatology Annual Meeting.
“The phase 2b data demonstrate sustained improvement of signs and symptoms for 28 weeks in adults with